Investment Management Software Enfusion Prices US$318.75 Million IPO

Accounts payable automation software Enfusion, Inc. (NYSE: ENFN) started publicly trading on the New York Stock Exchange today. The firm’s initial public offering is looking to raise US$318.75 million.

The offering will be conducted through the issuance of 18.75 million Class A common shares selling at US$17.00 per share. Out of this, around 3.43 million shares will be sold by the company’s existing stockholders while the remaining 15.32 million shares will be offered by the company itself.

The company granted the underwriters a 30-day over-allotment option to purchase additional 2.81 million common shares at the same IPO price. Morgan Stanley & Co. and Goldman Sachs & Co. are all acting as joint lead bookrunners for the said offering.

The firm also relayed that it intends to use the offering proceeds to purchase equity interests in its operating subsidiary Enfusion Ltd. which in turn will use the funds to repay indebtedness and pay IPO-related expenses.

The offering is expected to close on October 25, 2021, subject to customary closing conditions.

Enfusion is a cloud-based investment management software platform aimed at streamlining the investment process by tying the front, middle, and back-office functions. The firm is currently present in nine global offices partnering with 600+ investment managers.


Information for this briefing was found via Sedar and the companies mentioned. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

The $30,000 Gold Case Just Got Stronger | Simon Marcotte

Why Silver’s Move Is ‘Scary’ to Some Miners | Frank Basa

Are Commodities Entering a Generational Cycle? | Terry Lynch

Recommended

CBS News Cuts Staff and Shuts Radio Network in Early Bari Weiss Era

Steadright Closes Out Financing, Raising $1.6 Million For Moroccan Strategy

Related News

Chinese Biotech Firm LianBio Prices US$325 Million Nasdaq IPO

Biotech company LianBio (Nasdaq: LIAN) started trading on the Nasdaq Global Market today. The Shanghai-based...

Monday, November 1, 2021, 02:07:00 PM

VerticalScope Issues 5.7 Million Shares, Raises $125.1 Million In Initial Public Offering

Toronto-based tech firm VerticalScope Holdings Inc. (TSX: FORA) closed its initial public offering today, raising...

Monday, June 21, 2021, 10:55:00 AM

SPAC Lakeshore Acquisition II Prices US$60 Million IPO

Special purpose acquisition company Lakeshore Acquisition II Corp. (Nasdaq: LBBBU) started trading publicly on the...

Wednesday, March 9, 2022, 12:06:00 PM

Biotech Firm CinCor Pharma Kicks Off Nasdaq IPO Roadshow

Clinical-stage biopharmaceutical company CinCor Pharma, Inc. is setting its sights on trading at the Nasdaq...

Tuesday, January 4, 2022, 02:36:00 PM

Tech Firm Actelis Networks Closes IPO, Raises US$16.9 Million

Networking solutions provider Actelis Networks (Nasdaq: ASNS) closed its initial public offering on the New...

Tuesday, May 24, 2022, 02:26:00 PM